A Randomized, Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced Non-Small-Cell Lung Adenocarcinoma
Phase of Trial: Phase III
Latest Information Update: 15 Feb 2019
Price : $35 *
At a glance
- Drugs Docetaxel (Primary) ; Ganetespib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms GALAXY-2
- Sponsors Synta Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 18 Aug 2016 This trial has been completed in Belgium as per European Clinical Trials Database record.
- 04 Nov 2015 Planned End Date changed from 1 Mar 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov.